[Comparative analysis of the use of levamisole and pyrogenal in the treatment of multiple sclerosis].
A series of 120 patients with multiple sclerosis was subjected to a clinico-immunological examination and treatment. In a group of patients receiving levamisole, improvement of the neurologic symptomatology was observed in 65% of the cases and that of the immunological indices in 97.5%. Pyrogenal treatment led to no improvement in the immunological parameters. Clinical improvement in this group was seen in only 17.8% of the patients. It is recommended that treatment with levamisole be conducted following the preliminary assessment of the sensitivity of the patient's lymphocytes to the drug in vitro.